{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily Top Stories - Oct 20, 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/bc147c06\"></iframe>","width":"100%","height":180,"duration":535,"description":"Daily - Oct 20, 2026 v2 - Show Notes\nGet personalized biotech intelligence and catalyst tracking from SOZO Intuition:\nhttps://sozointuition.com\nCHAPTERS\n00:00 Biotech Daily Briefing\n00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania\n01:32 RAP-219 Validates Selective Mechanism in Acute Mania\n02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma\n03:02 Casdatifan Delivers 35-Month Median Overall Survival\n03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease\n04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI\n05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros\n06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial\n07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric\n07:50 Looking ahead\n08:31 SOZO Intuition\nSUMMARY\nWelcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes.\nCHAPTERS AND SOURCES\n00:00 - Biotech Daily Briefing\n00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar Mania\nRapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:\nhttps://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm\nPolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:\nhttps://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026\n01:32 - RAP-219 Validates Selective...","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}